Synthesis, Structure, and Anticancer Activity of a Dinuclear Organoplatinum(IV) Complex Stabilized by Adenine
The dinuclear platinum(IV) compound {Pt(CH<sub>3</sub>)<sub>3</sub>}<sub>2</sub>(μ-I)<sub>2</sub>(μ-adenine) (abbreviated Pt<sub>2</sub>ad), obtained by treating cubic [Pt<sup>IV</sup>(CH<sub>3</sub>)<sub>3<...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Compounds |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-6918/5/2/16 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The dinuclear platinum(IV) compound {Pt(CH<sub>3</sub>)<sub>3</sub>}<sub>2</sub>(μ-I)<sub>2</sub>(μ-adenine) (abbreviated Pt<sub>2</sub>ad), obtained by treating cubic [Pt<sup>IV</sup>(CH<sub>3</sub>)<sub>3</sub>(μ<sub>3</sub>-I)]<sub>4</sub> with two equivalents of adenine, was isolated and structurally characterized by single crystal X-ray diffraction. The National Cancer Institute Developmental Therapeutics Program’s in vitro sulforhodamine B assays showed Pt<sub>2</sub>ad to be particularly cytotoxic against the central nervous system cancer cell line SF-539, and the human renal carcinoma cell line RXF-393. Furthermore, Pt<sub>2</sub>ad displayed some degree of cytotoxicity against non-small cell lung cancer (NCI-H522), colon cancer (HCC-2998, HCT-116, HT29, and SW-620), melanoma (LOX-IMVI, Malme-3M, M14, MDA-MB-435, SK-MEL-28, and UACC-62), ovarian cancer (OVCAR-5), renal carcinoma (A498), and triple negative breast cancer (BT-549, MDA-MB-231, and MDA-MB-468) cells. Although anticancer studies involving some adenine platinum(II) compounds have been reported, this study marks the first assessment of the anticancer activity of an adenine platinum(IV) complex. |
|---|---|
| ISSN: | 2673-6918 |